India, March 17 -- Swiss firmmAbTree Biologics AGhas signed an exclusive co-development and commercialisation partnership withShilpa Biologicals PvtLtd(a fully owned subsidiary of Raichur-based Shilpa Medicare Limited) for its novel biologic asset [a checkpoint inhibitor] for immuno-oncological applications.

Under the terms of the strategic agreement, Shilpa Biologicals will support both development - including clinical studies - as well as long-term commercial supply with GMP manufacturing. Additionally, Shilpa Group will provide mAbTree access to India and several global markets through its extensive partner network.

This programme aims to develop a fully human monoclonal antibody against a novel immune checkpoint protein that enables...